Holen Sie sich die Stockscreener-App
1.28
5.79%
0.07
Vorhandelsmarkt:
1.38
0.10
+7.81%
Schlusskurs vom Vortag:
$1.21
Offen:
$1.21
24-Stunden-Volumen:
338.07K
Relative Volume:
0.36
Marktkapitalisierung:
$11.58M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.23M
KGV:
-0.086
EPS:
-14.8777
Netto-Cashflow:
$-15.31M
1W Leistung:
-2.29%
1M Leistung:
-36.32%
6M Leistung:
-96.95%
1J Leistung:
-90.15%
1-Tages-Spanne:
$1.21
$1.30
1-Wochen-Bereich:
$1.15
$1.355
52-Wochen-Spanne:
$1.15
$55.00
Genprex Inc Stock (GNPX) Company Profile
Firmenname
Genprex Inc
Sektor
Branche
Telefon
512-537-7997
Adresse
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
1.28 | 11.58M | 0 | -16.23M | -15.31M | -14.88 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-01-26 | Eingeleitet | National Securities | Buy |
| 2019-04-29 | Eingeleitet | Noble Capital Markets | Outperform |
Genprex Inc Aktie (GNPX) Neueste Nachrichten
Genprex director Longnecker sells shares worth $22 - Investing.com
Genprex director Longnecker sells shares worth $22 By Investing.com - Investing.com South Africa
Genprex (GNPX) director logs small stock sales mainly for taxes - Stock Titan
GNPX Technical Analysis | Trend, Signals & Chart Patterns | GENPREX INC (NASDAQ:GNPX) - ChartMill
Surprises Report: What are the analyst revisions for Guess IncIs Genprex Inc stock a good investment in YEARWeekly Stock Analysis & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
GNPX Should I Buy - Intellectia AI
US Stocks Recap: What is the PEG ratio of AXSM2026 WrapUp & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Genprex Shares Hit Annual Low Despite Stronger-Than-Expected Earnings - AD HOC NEWS
GNPX SEC FilingsGenprex Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Genprex (NASDAQ: GNPX) advances REQORSA trials, eyes diabetes gene therapy - Stock Titan
Genprex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Published on: 2026-03-30 13:10:35 - baoquankhu1.vn
Genprex, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Top Ranking Stock Picker From Congress Is Back Buying Small Cap Stocks Again: Here Are The Tickers - Benzinga
IPO Launch: Whats the beta of Genprex Inc stock2026 Drop Watch & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Dip Buying: Will Genprex Inc benefit from green energy policiesQuarterly Profit Review & Free Long-Term Investment Growth Plans - baoquankhu1.vn
GNPX Stock Chart | GENPREX INC (NASDAQ:GNPX) - ChartMill
Performance Recap: What are the analyst revisions for Guess IncIs Genprex Inc stock a good investment in YEAR2026 Selloffs & Weekly Chart Analysis and Guides - baoquankhu1.vn
Genprex, Inc.: Fundamental Analysis and Financial Ratings | 2DE | US3724463027 - marketscreener.com
GNPX Earnings History & Surprises | EPS & Revenue Results | GENPREX INC (NASDAQ:GNPX) - ChartMill
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting - BioSpace
Genprex collaborators to present lung cancer data at AACR meeting By Investing.com - Investing.com Australia
Genprex presents positive preclinical REQORSA data at AACR showing biomarkers and combo efficacy - TradingView
Genprex Highlights New Reqorsa Preclinical Data at AACR - TipRanks
GNPX: Genprex Researchers to Present at AACR 2026 with Promising Lung Cancer Data - GuruFocus
Genprex collaborators to present lung cancer data at AACR meeting - Investing.com
Genprex (NASDAQ: GNPX) posts positive preclinical data on REQORSA in NSCLC - Stock Titan
New Highs: Will Genprex Inc benefit from green energy policiesTrade Risk Assessment & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Genprex to Participate at BIO Europe Spring 2026 - GuruFocus
GNPX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Aug Closing: Will Genprex Inc outperform tech stocksMarket Activity Report & Weekly High Return Forecasts - baoquankhu1.vn
Trend Recap: Will Genprex Inc outperform tech stocksWeekly Gains Report & Technical Confirmation Trade Alerts - baoquankhu1.vn
Genprex receives patent approval in Australia for cancer therapy - Investing.com Nigeria
Congressman Who Bought Small-Cap Stocks In 2025 Is Back With New 2026 Pick: Here's What He's Buying - Yahoo Finance
GNPX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Genprex (NASDAQ: GNPX) CMO has shares withheld to cover RSU taxes - Stock Titan
Genprex (GNPX) CEO reports 9,330-share tax-withholding disposition - Stock Titan
Congressional Trading Activity Insights - Intellectia AI
Genprex bags major patent wins in Japan & Europe for REQORSA cancer therapy - Indian Pharma Post
Genprex Advances Cancer Therapy Strategy with Key International Patents - AD HOC NEWS
Genprex receives Japanese and European patents for cancer therapy By Investing.com - Investing.com India
Genprex stock jumps on Japan, Europe patent approvals By Investing.com - Investing.com Nigeria
Genprex stock jumps on Japan, Europe patent approvals - Investing.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
GENPREX, INC.COMMON STOCKTim Moore Congressional Trade on Feb. 05, 2026 - Quiver Quantitative
Genprex (GNPX) Gains Global Patent Approvals for Innovative Canc - GuruFocus
Genprex Secures Key Global Patents for REQORSA Therapy - TipRanks
Genprex receives Japanese and European patents for cancer therapy - Investing.com
Genprex secures Japan, EU patents for REQORSA combos, bolstering Acclaim-3 IP and trial - TradingView
Finanzdaten der Genprex Inc-Aktie (GNPX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):